RE:newsHere is the news that MUSLIX is refering to:
MONTREAL, Oct. 03, 2019 (GLOBE NEWSWIRE) - Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that new 48-week data from the TMB-311 Extended Study confirms that Trogarzo® (ibalizumab) provides long-lasting viral suppression and a consistent safety profile with the pivotal Phase III study of 24 weeks. The results of the study were presented today at IDWeek ™ in Washington, DC, USA. The results come from the TMB-311 Extended Access Protocol. A total of 38 patients were enrolled in Cohort 2. These patients had a viral load less than 1000 copies / mL, were resistant to at least one antiretroviral of three different classes and had a viral sensitivity to at least one antiretroviral. In Cohort 2 patients, the reduction in viral load at 24 weeks and at 48 weeks was similar. Respectively, 46% and 47% of patients taking Trogarzo®, combined with an Optimized Baseline Treatment (OBT), including at least one functional agent, had their viral load reduced and dropped below 50 copies / mL. In addition, at 24 but also at 48 weeks, the reduction in median viral load was -2.6 log10 copies / mL. This far exceeds the original goal of a reduction? 0.5 log10 copies / mL. Notably, a viral load below 50 copies / mL is considered undetectable and patients can not pass HIV to others.
FTV.